Fermion Secures Series B Financing to Advance AI-Driven Drug Development
Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B...
Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform
Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A...
Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials
China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with...
WeDoctor Partners with Jinan Innovation Zone to Launch Dual Healthcare Platform
China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation...
ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has...
VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed
China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products...
Merck KGaA Launches Uptune Program in Asia, Offers Startups Up to €100,000
Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up...
Pfizer Launches Cejemly in China for Stage III NSCLC, Expands Immunotherapy Reach
Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell...
Sihuan Pharma to Sell Generic Drug Businesses, Shift Focus to Aesthetics and Biologics
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced plans to divest a portion of...
Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment
China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...
Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment
Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...
CStone Pharmaceuticals’ Gavreto Wins Hong Kong Approval for RET Fusion NSCLC
CStone Pharmaceuticals (HKG: 2616) announced that its RET inhibitor Gavreto (pralsetinib) has received marketing approval...
NMPA Approves RocketHeart’s LV Assist System and Our United Group’s Radiation Therapy Device
The National Medical Products Administration (NMPA) has approved marketing for two innovative medical devices: RocketHeart’s...
Ping An Good Doctor Partners with China Biotech Services for Cancer Testing and BNCT Treatment
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...
Kelun Pharma’s SKB264 ADC Receives NMPA Green Light for Phase II Solid Tumor Study
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its antibody drug conjugate (ADC)...
Luye Pharma Initiates Phase III Study of Trulicity Biosimilar BA5101 in China
China-based Luye Pharma Group (HKG: 2186) announced the initiation of a Phase III clinical study...
Shanghai Electric and Siemens Partner on Localization of High-End Medical Equipment
China’s Shanghai Electric Group has partnered with Germany-based Siemens Healthineers to localize high-end medical equipment,...
Beijing Science Sun’s LZ901 Shingles Vaccine Receives FDA IND Approval
China-based Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced that its subsidiary Beijing Luzhu...
Ningbo HicRen Biotech Completes RMB100M Pre-Series C Financing for Orthopedic Robots
Ningbo HicRen Biotechnology Co., Ltd, a China-based robotics-driven minimally invasive orthopedics platform, announced the completion...
CStone Pharmaceuticals Explores Strategic Options Including Buyout
China-based CStone Pharmaceuticals (HKG: 2616) is evaluating strategic options, including a potential buyout, according to...